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Abstract
Some of the most exciting parts of work in the pharmaceutical industry are the steps lead-
ing up to drug discovery. This process can be oversimplified by describing it as a screen-
ing campaign involving the systematic testing of many compounds in a test relevant to 
a given pathology. This naïve description takes place without taking into consideration 
the numerous key steps that led up to the screening or the steps that might follow. The 
present chapter describes this whole process as it was conducted in our company dur-
ing our early drug discovery activities. First, the purpose of the procedures is described 
and rationalized. Next follows a series of mostly published examples from our own 
work illustrating the various steps of the process from cloning to biophysics, including 
expression systems and membrane-bound protein purifications. We believe that what is 
described here presents an example of how pharmaceutical industry research can orga-
nize its platform(s) when the goal is to find and qualify a new preclinical drug candidate 
using cutting-edge technologies and a lot of hard work.
Keywords: drug discovery, validation, cloning & expression, biophysics, structural 
biology, organization
1. Introduction
Drug discovery involves a suite of processes as part of a program aimed at finding drug thera-
pies for diseases. These programs encompass many different scientific steps from validation 
of the target (or attempts to do so) and characterization of the hits until the selection of can-
didates for medicinal chemistry programs. We felt that an accurate description of those steps 
has not previously been available and that such a description could be interesting.
In PubMed®, several thousand publications exist with the term ‘drug discovery’ in their titles. 
Most frequently, these reports share with readers how important the authors’ particular area of 
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expertise is in this domain, covering almost everything from crystallography to screening and 
high-content screening, origin of the screened molecules, compound libraries, sample conser-
vation, biochemical approaches, microarrays, proteomics, and aptamers. These publications 
are a useful source of inspiration for each new program. Clearly, the first step in drug discovery 
is inspired by the state of the art, and the literature will help drive research towards the ‘bench-
to-bed’ goal of finding a new molecule that will eradicate some disease that affects our society.
We feel, however, that the complete picture of such processes is not very often characterized. 
Thus, here we exemplify how we built our drug discovery (DD) platform on basic science 
with the goal of following, in a unique location (a set of specialized laboratories), the logical 
successive steps of drug discovery from ideas to first hits. An oversimplified picture of the 
logical progression from start to end of these processes can be seen in Figure 1.
This configuration did not preclude failures but probably helped forward our successes. In 
the pharmaceutical industry, the attrition rate is around 9 of 10 projects, meaning that only 1 
project in 10 will have a slight chance of ending up in clinical development, and a further 2–3 
out of 5 of these will have a chance to reach patients. Therefore, in preclinical research, scien-
tists will try to deliver on time and with maximal rigor the tools necessary for the pathologi-
cal problem to be at least partially solved. In 9 cases out of 10, the efforts will be vain, as the 
programs will be terminated, either for lack of results or for a change in strategy. The reasons 
for attrition are many, and a key to decreasing number is certainly a better characterization 
of molecules entering the medicinal chemistry program that will drive candidates from hit to 
Figure 1. Schematic representation of a drug discovery process. Note that the exploratory/validation of the target process 
is not part of the schedule. Rather, these two steps might take several years to complete upstream.
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lead. Among the characterizations that are essential is the specificity of the molecule within its 
class of targets (e.g., one given kinase among the 800 in the kinome) or its specificity towards 
the rest of the genome-encoded proteins. Another key is a better understanding of the mole-
cule-target relationship at the atom level.
In addition to these scientific aspects, daily nonscientific aspects of business also require atten-
tion. Examples include practical questions, such as ‘Can we hire new specialists to explore 
and assess a new field for a particular problem?’; economic questions, such as ‘Can we spend 
the money necessary to acquire a particular technology’; and time-related questions, such as 
‘Can we spend the 12 to 20 months to deliver the results after the necessary assessment for a 
new technology/technique?’
Below, we offer our view through our experiences with all of these aspects, reflecting the work 
of a laboratory ultimately consisting of about 70 people, with some impressive achievements.
2. Basic sciences, organization?
Our group has a “simple” core job: the discovery of drug candidates. Programs are based on two 
types of knowledge: the pharmacological background linked to the various areas of therapeutics 
(e.g. cancer, cardiology, or neurosciences) and the techniques needed to explore the molecular 
side of the program (e.g. molecular biology, cellular biology, biochemistry,  structural biology), 
in other words ‘basic sciences for discovery’. That basis was a mixture of molecular and cellular 
pharmacology techniques that allowed starting from a protein target and finishing with a com-
pound (or several) that interfered with this target in a reasonably specific manner. To this were 
added chemistry (for the compound collection) and molecular modeling (for dynamics and struc-
tural biology data interpretation). One of the major challenges was the identification of a given 
target in the pathological process, its role in the pathology, and its manipulation. These necessi-
ties meant that we also needed upstream access to experimental techniques such as siRNA, KO 
mice, alternative laboratory animals (such as yeast, flies, and zebrafish [1], and Caenorhabditis 
elegans [2]) often at a time when these techniques were barely validated. It also meant that we fre-
quently had to make the choice of collaboration rather than pursuing these techniques internally.
2.1. Exploring pathology
“Exploring” means several things in this context, from exploring the disease to exploring the 
tools and the literature to validate a target. The literature is rather scarce in this context, but 
one resource is the essay by Scudamore, who tries to make us understand how difficult and 
diverse this area could be [3].
The exploration of pathology is the main objective of academia, but industry faces a chal-
lenging problem. Should it run brand-new programs using its internal research capacities or 
should it collaborate with academia to help them run such program? Considering that part 
of the work in industry is to choose relevant targets accessible to chemistry (even if chemistry 
has broadened its borders for the last decades) and that are truly and undoubtedly linked to 
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a pathological situation, it cannot start several million-euro projects without a validation that 
convinces everyone that the end discovery will help the patient.
Thus, industry must equilibrate its efforts among internal, confidential, and secured experi-
ments that would identify and elucidate the role of a target in a pathological process while 
scouting externally in academia and biotech for new ideas, concepts, targets, and even some-
times candidates. In these last cases, however, internal reproduction of key data should not be 
underestimated in terms of time, money, and results (see Section 2.2).
We were involved intensively in several such programs. For example, N-myristoyltransferase 
is a protein-modifying enzyme with a key role in addressing substrate to the membrane [4], 
including oncogenes or viral proteins [5, 6]. Our discovery that one isoform was associated 
with rough endoplasmic reticulum led us to believe that this particular isoform potentially 
had a role in pro-virion maturation [7]. On another front, we discovered/characterized a new 
activity for the enzyme autotaxin, a lysophospholipase D, the activity of which explained 
why that protein was previously believed to be a migration factor [8, 9]. This enzyme could 
be deeply involved in fat accumulation processes [10] and in metastasis [11]. We pursued this 
program up to the discovery and characterization of a hit compound that failed for stability 
reasons [12]. Another example is N-arylalkylamine acetyltransferase (AANAT), an enzyme 
involved in the synthesis of melatonin, of which we characterized the properties of the human 
isoform [13], while its importance in regulating melatonin synthesis had been demonstrated 
[14]. Our approach to the uncoupling proteins was similar to this. We thought that UCP3 
might be a good target for diabesity, if we could find an activator of this enzyme. The chal-
lenging idea was that by accelerating proton exchange, one could reasonably enhance the heat 
dispersed by muscles. We thus started to study this particular enzyme in various contexts [15, 
16], up to an in vivo model for which elegant techniques were developed [17, 18].
Opportunities are numerous for scientists in the core of a network. As noted, the challenge is 
always to be original enough but not too much involved in fundamental research because the 
time frame is simply not suitable to the business of industry, at least for the most part.
2.2. Validating targets (as actor in a pathology)
The validation of the implied involvement of a given molecular target in a pathological 
process requires many different approaches and technical applications. A special issue of 
Current Topics in Medicinal Chemistry was published in 2017 on this subject (see the editorial 
by Henderson and Gibert in [19]). Furthermore, Kaelin published an interesting paper [20] 
on the pitfalls in preclinical cancer target validation. Indeed, one of the main aspects of the 
Kaelin essay is that many experiments reported even in major journals are hard to reproduce 
independently, if at all, and thus validation is a difficult task. Obviously, this has been an end-
less debate in the scientific community, and commenting on it further here will not add to the 
discussion. The primum movens is not the same between academia and industry. Basically, it 
is fair to say that the protocols are not regularly described in enough detail to be easily repro-
ducible in a different laboratory context.
Without a strong, scientific knowledge about the pathology, cures will not be found except by 
chance. Thus, being able to present our program in a way that is reproducible is important. 
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One has to be able to ensure (or be reasonably sure) that the observations made are linked to 
the ‘pathological’ situation and not to experiment-generated artifacts. Of course, achieving 
this goal requires a mixture of pure luck, hard work, prepared minds, curiosity, and willing-
ness to move forward.
Most of the time, however, only a portion of these experiments is feasible, either for timescale 
reasons or for cost. Therefore, the choice is often made to go to primary approaches such as 
knockout cells or knockout animals. We reported such an approach with cells [21], knocking 
out the product of a gene by measuring the catalytic activity of the corresponding enzyme, 
spontaneously expressed in a cell line, HT22, after siRNA and shRNA treatments. It took a 
double transfection with a shRNA encoding a siRNA specific of QR2 to knock down only 80% 
of the catalytic activity of the enzyme. This result suggests that knocking out a spontaneously 
expressed protein in a cell line—especially in a cancer cell line, which is often pluri-nuclear—is 
difficult, if not impossible beyond knocking it down somehow. It is interesting to compare this 
type of data, including those we obtained in similar conditions but that remained unpublished, 
with claims that cocktails of siRNA transfected directly into (cancer) cells would kill the activ-
ity of an enzyme within hours (if not minutes). A recent review on the subject [22] emphasized 
the fact that RNAi studies have been used and abused, suggesting that the key role of those 
RNAs should be kept to a tightly verified level to gain from this outstanding technology and 
fix once and for all the problem of in cellulo identification and engagement of a target in a 
given pathology. Technologies involving nucleases and CRISPR have changed the technologi-
cal landscape of cellular biology because these techniques lead to complete knockout and are 
almost universal—until exceptions to their effectiveness or accuracy start to emerge.
Cellular validations are often not complete enough to give strong support to a pathophysi-
ological hypothesis. It is thus necessary to move to another approach: the genetic deletion of 
the target in mice, or, more recently, in rats. The bias of this approach, besides its cost and 
often the length of the process, is linked to the potential capacity of animals to compensate for 
the absence of a particular gene (or the absence of a particular catalytic activity). This compen-
sation might happen often, but proofs of such situations are rare. The two main difficulties we 
have encountered were either the lethality of the KO in mouse embryos [23] or the complete 
absence of an obvious phenotype due to the loss of this particular gene [24, 25], a surprisingly 
frequent feature. The former example offers a rare case. When we mutated a single amino 
acid in the catalytic site of lysophospholipase D, which renders the enzyme completely cata-
lytically inactive, the mouse embryos died in the very early stages of their development [23]. 
This outcome was unexpected but proved at least that the enzyme activity was a key player 
in mouse embryogenesis [26, 27]. Knockout animals can also be fantastic tools to prove that 
the compound engages the target. For instance, our antagonist of the melanin-concentrating 
hormone (MCH) receptor, S38151, has no activity in MCHR1 KO animals, while it reduces 
feeding wild-type ones, demonstrating that the compound exerts its expected activity only 
through its binding to the receptor [28]. Other examples have been generated in our DD plat-
form, such as with the deletion of trace amine 1 receptors, revealing the involvement of those 
receptors in the actions of the drug Ecstasy (MDMA) [29]. Unexpected properties of the modi-
fied animals are sometimes found long after the knockout has been performed, resulting in 
the resuscitation of the program. For example, the knockout of Ucp2, an uncoupling protein 
expressed in almost all mouse tissues, confers an unexpected resistance to Toxoplasma gondii 
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infection [30]. Finally, particularly difficult is the choice of the mouse strain usable for the 
KO line. Indeed, some examples of animals totally deprived of circulating melatonin led to 
slightly different observations about the impact of the knockout when compared to a strain 
presenting a “normal” level of circadian melatonin [31]; thus, not only are some strains par-
tially blind but consequently their daily rhythm is profoundly affected.
Again, recent progress in cellular surgery, thanks to CRISPR techniques [32], might make the 
development of KO animals faster and even commonplace in the near future, but today the 
process remains a lengthy one.
Alternatively, in addition to these genetic manipulations in vivo or in cellulo, the pharmaco-
logical approach remains a possibility. Strategically, though, it is rare for a pharmacological 
set of tools for a “new” target to exist beforehand, and these molecules need to be specific 
and/or powerful enough to help validate the system. An upstream decision must be made 
about whether the high-throughput screening (HTS) approach that will probably deliver 
compounds can be used very early in the discovery process to bring tools rather than drug 
candidates to validate the target around which the program was/will be built. This theoreti-
cal situation can provide the community with very early tools to validate their activities (see 
reviews by [33, 34]).
Of interest, another approach has become possible in recent years, thanks to our collabora-
tive work with the Shanghai Institute of Materia Medica (SIMM): a validation with mol-
ecules of poor specificity but engaging the target. Indeed, as soon as the first compounds are 
issued from this screening process, even if they are far from perfect, attempting high doses 
of such molecules on an animal model relevant to the pathology brings interesting and 
important information about the validation of the pathological hypothesis. Only a couple of 
examples have been published following these attempts, one with thioredoxin-interacting 
protein (i.e., TixNip) modulators [35] and the other with a gpr119 antagonist [36].
2.3. Cloning/expressing/purifying the targets
Obviously, targets come from independent experimental observations that have suggested 
their role in a given pathology in a given system through the measure of activity such as a 
catalytic activity or a potential binding site. Ultimately, purification should be performed and 
should lead to the unequivocal characterization of the protein the program targets. A recent 
trend is to consider that this given protein is a brick in the pathway(s) leading to the pathol-
ogy. In this framework, the protein should retain its cellular context to allow for consideration 
of the potential role of its partners and cellular neighborhood. This situation is no doubt opti-
mal. Nevertheless, finding compounds that will hit the target should begin with a simplifica-
tion of the system. Without this simplification, one should consider the multiple interferences 
from the cell milieu (see also the HCS discussion below, Section 2.6.3).
This is an old debate between the pros and cons of protein purification. The pros consider that 
the candidate molecules should be aiming directly at the protein and that structural biology 
will deliver key information on the target-molecule relationship providing that the system is 
as simple as possible. The cons remind us that inside the cytosol, an enzyme interacts or is in 
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proximity to many other proteins, some of which can involve interference. Rather than being 
an assortment of simple linear pathways, the cytosol in reality is more like a bag of marbles—
proteins—rolling around and bumping into each other.
As far as enzymes are concerned, is it acceptable to work on a partially purified extract or 
should we aim for the pure version? For screening purposes (the nec plus ultra of the work of 
such a DD platform), the need for membranes overexpressing a receptor is key to the success 
of the next processes, so are there alternatives?
Cloning remains a source of novelty. Obviously, using already published sequences for new 
targets involves a bias because these targets are already known in the literature, so that the 
results with them are less novel that would be desirable for the drug market. Thus, cloning 
efforts of new, not already described targets, are at best a challenge. Our first attempts were to 
control the expression of receptors or enzymes, together with an associated protein (whether 
naturally associated or needed for building an assay for this target). Particularly interesting 
was trying to find ways by which the expression of two proteins—or two peptides—could be 
stoichiometric. For such a goal, the best approach was to use and organize IRES promoters 
in different geometries [37]. This method led us to the successful expression of several multi-
peptide proteins, such as the nicotinic receptors.
It is interesting to see now the progress in what was once called cellular surgery, first with 
nuclease approaches and now with CRISPR. In past years, we used nuclease-based tech-
niques to produce cellular models (most of the time, unfortunately, based on cancer cells) 
that would express a single copy of the transgene, integrated into the cell genome at a single, 
neutral position [38]. This method was interesting because for comparisons of the molecular 
pharmacology of a receptor from different species, often from human and one or two rodent 
species, the comparison was more relevant because only the sequence of the receptors drove 
the differences between the pharmacological profiles. Indeed, it was integrated into the same 
cellular host—CHO or HEK cells—at an identical ‘neutral’ position, with a single copy of the 
gene, leading to a validity and accuracy in the data that was difficult to obtain whenever the 
transfection was less controlled.
When the enzymes have already been described/cloned, expression is easier in a host cell—
often bacteria—but then the purification (of an active enzyme) often becomes the key. Typical 
examples of such purification strategies can be found for chymase [39], AANAT [13, 40], and 
indoleamine-2,3-dioxygenase [41].
Regarding other aspects of research the DD platform has conducted, we should mention 
work on already known targets that suddenly take on added interest because they turn out 
to be involved in an unexpected physiopathological situation. One example is the role of 
quinone reductase 2 beyond its presumed detoxifying role. The enzyme has been associated 
with cognitive processes on the one hand [42] and with melatoninergic systems on the other 
[43]. Aware of these observations, our attempt was to build a network around the notion 
that inhibitors of this enzyme could be interesting tools or drugs in understanding cognition 
and cognition deficits [24, 44], as well as better characterizing the MPTP Parkinson model 
in mice [45, 46]. We reported several examples in which we explored new pathways and 
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found evidence for new proteins or new activities. For example, the observation that lysoPLD 
activity was present and active in an adipocyte culture medium led us to hypothesize that 
this medium contained a protein capable of catalyzing the breakdown of lyso-phosphatidyl-
choline. We reported this discovery [8], after having purified, characterized, and discovered 
alternative splicing forms [9], built the KO mice [23], and started a search for active inhibitors 
[12]. It is interesting to look at it from a time-frame perspective. Indeed, the initial observa-
tions were made in 1999 while our initial report was published in 2003 [8] and the last report 
on the compound, S32826, in 2008 [12]. Thus, it took about 10 years before all tools were in 
place and the program had sufficient experimental evidence to allow for a process to lead to 
an actual drug discovery program per se. Only in 2011 evidence in the literature has shown the 
probable implication of this target in metastasis [47]. The work on autotaxin also concerned 
an already known motility factor [48] that turned out to be an enzyme generating this motility 
factor, with a potential role in metastasis [47, 49].
Broadening the observation that N-myristoyltransferase was key to the maturation and deliv-
ery of oncoproteins, such as src, to the membrane, we became interested in the other proteins 
that were myristoylated [6] and sought to differentiate their cytosolic activity from the poorly 
described membrane-associated activity. These studies led us to wonder if there was a target 
for inhibitors that would turn out to be antiviral compounds (myristoylation of the membrane 
viral protein gag is key in the virus life cycle). Very early on, we became interested also in 
kinases and some of their modifying enzymes (e.g., NMT, see above). Indeed, we started our 
program by choosing to explore the main tyrosine protein kinase expressed in the HL60 cancer 
cell line [50, 51] and purification was the only option at a time when cloning was rather rare.
We still believe that following the expression of the target (enzyme) in bacteria, for instance, 
activity must be purified to homogeneity. Indeed, the further process of testing the activity 
should lead to unambiguous attribution to the target protein and not to a similar activity cata-
lyzed by a bacterial endogenous enzyme. Therefore, much effort was often put into the purifi-
cation process, even though the current literature reflects a lack of enthusiasm about obtaining 
a pure enzyme. Furthermore, the need for biophysical as well as structural data necessitates a 
pure product, in any case. Therefore, what is done at that stage serves at least three purposes: 
obtaining uniformity of the enzyme in the preparations; gaining the possibility of measuring 
unambiguously the relationship between molecules and their targets; and finally, achieving 
crystallogenesis, which requires the purest possible preparation to start with.
Considering receptors, the situation might be slightly more favorable to a less simplified sys-
tem. Indeed, the main property of receptor binding is certainly that the binder is specific to the 
receptor; thus, considering membranes as an acceptable receptacle for receptor studies seems 
to be an adequate compromise. For instance, in a program linked to our historical involve-
ment in melatonin receptor pharmacology, we had to find a way to check for the activity of 
agonist candidates in an in vivo model of depression that was a non-rodent and diurnal ani-
mal (melatonin being heavily involved as a master switch of the circadian rhythm as well as 
the circannual one) [52, 53]. Such models were not that common, especially at a time when the 
exact nature of the chronobiology was not understood. We then turned to a sheep model with 
the difficulty that, at that time, it was believed that two animals were known to be natural 
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knockouts for one of the melatonin receptors (MT2). Although this was clearly demonstrated for one strain of hamster [54], it was less clear for the sheep. Thus, we embarked on a chal-
lenge to finally clone, express, and characterize the MT2 receptor from sheep, destroying this myth at the same time [55]. Such approaches became one of our interests in our multiple 
attempts to crystalize G-protein-coupled receptors (see also the structural biology section, 
below). In brief, a survey of the sequences of the receptors of a common family (e.g., melato-
nin) in various animals indicated variations of sequences with retention of specificity (towards 
melatonin). By measuring the thermal stability of the receptors, we can deduce the strongest 
structure that could be amenable to expression, solubilization, purification, and crystallogen-
esis attempts [56, 57], as anticipated a few years ago [58]. In other words, despite the apparent 
futility, cloning/expressing receptors from multiple sources might lead to findings of major 
importance. More recently, however, an attempt to clone the second melatonin receptor from 
the European hamster, previously reported as a natural knockout (as in the other hamster 
species), partially failed because of difficulty establishing the appropriate conditions to copy 
a particularly rich G-C region of the gene, as we had done for the sheep MT2 receptor [55]. Finally, in our quest for stable versions of the melatonin receptors, we engaged in a series 
of cloning programs of these GPCRs from different animals, including bats, birds, snakes, 
and various mammals, most of which were not published (Guenin and Boutin, unpublished). 
Indeed, we ended up trying to characterize the melatonin receptors of the strangest mammal, 
the platypus. We did clone the ancestor of gpr50, a.k.a., Mel1c, and characterized its unique 
pharmacology; gpr50 has lost its melatonin-binding capacity in all mammals except for the 
platypus (Gautier et al., in press). Following the same line of work, we started a program 
aimed at validating the existence of a third melatonin-binding site [59], as reported earlier 
[60], to finally attempt and succeed in purifying it [43]. This effort led us to a series of studies 
demonstrating the key role of this enzyme in many different contexts [61, 62].
Of course, channels and receptors (as well as membrane-associated enzymes) require a sys-
tem of expression in which the channel activity can be followed unambiguously because quite 
often, purification of these proteins is extremely difficult to achieve.
2.4. Testing the enzyme or the receptor (or else)
As noted, and as can be understood from the scheme in Figure 1, testing the enzyme or the 
receptor is the cornerstone of the whole process. Assaying a target involves several important 
requirements: the test should be robust, fast but reproducible, easy to handle and cheap and 
if possible should address only the activity that is targeted with minimal interference from the 
compounds in the assay ingredients. Several reviews have been published on this issue. For 
instance, the race for label-free solutions [63] or the use of instruments that measure directly 
the amount of product formed (or consumed) during the assay [64] are two perspectives on 
the never-ending moving/changing landscape that rises into view as soon as the screening 
process is involved. Books could be written on the way a screen must or can be done. Below 
are just a few examples of the choices we made.
Choosing the right test is a key decision that will influence the rest of the program. In the past, 
we spent some time trying to identify the best assay for our kinase program and evaluated the 
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whole literature for the best possible options [65] before finally attempting to run our own orig-
inal version [66]. We frequently found that the assay described for our target class was not fully 
adaptable to our instruments or presented potential interference with the assay component(s). 
Several dozens of assays were adapted from the literature and/or from the material we had in 
hand, such as the systematic use of HPLC [9, 39, 41, 67–69] and more recently, mass spectrom-
etry [70]. Worth noting here is the use of a global technique such as NMR. Indeed, a feature of 
this method is of great interest for us: it has poor sensitivity but a high robustness [71] and can 
be used not only for screening purpose but also for monitoring poor-affinity target/compound 
interactions, as in the first step of the search for receptor ligands. In addition to its obvious 
use as an analysis technique, we have adapted this method in various frames, including a 
way to better trace enzymatic activity [72], use a fluorine-labeled spy molecule as a ligand for 
an enzyme (that screened compounds can chase) [73], or verify changes in a component of a 
reaction [74]. These techniques are all automatable and thus can be used with less staff power 
as long as the automate is running by itself—day and night—and the validation of the assay 
guarantees stability of the components over time.
When turning to non-enzymatic assays, such as receptor binding or protein-protein interac-
tion, the constructs necessary to reveal the activity of the candidate compounds might be 
complex. For the receptor assays, where binding is the known first step, the functionality is 
the key information: e.g., agonists as well as antagonists are ligands in a binding assay, and 
only the functional assay—often cellular [75–77], but with exceptions [78]—thus should be 
able to distinguish between both entity types.
The recent evolution in understanding of receptor bias ligands has considerably changed our 
view of receptology. Indeed, for GPCR studies, compounds can be specific antagonists of a given 
signaling pathway (see, for example, a recent survey on the melatonin receptors [79]) but partial 
agonists in another measured pathway. Even if the bottom line is that an agonist should lead to 
the internalization of the receptor—which the antagonists should not—there will be exceptions 
and changes in paradigm(s) ([80], for instance, and Legros and Boutin [unpublished]).
Of course, in some cases, we had to develop and assess a completely new assay, such as when 
we addressed the difficult question of PPARγ ligands and had to use a new method of bind-
ing onto this soluble protein [81].
Globally, it is fair to say that four molecular target types cover most of the druggable bio-
chemistry of living organisms: the enzymes, receptors, channels, and protein-protein interac-
tions. In fact, our view is that a full spectrum of possible techniques should be available to 
play with and adapt to the current project, while validating as much as possible the potential 
biases of such techniques. We decided very early to double-check the results of a screen (i.e., 
validate the hits) by using an orthogonal assay (see Section 2.9), that is, an assay that does not 
have the same technical approach as the initial one.
2.5. Automatizing the assay
Automation is the capacity for an industrial laboratory to run literally hundreds or thou-
sands of assays a day and be able to extract from this formidable amount of data a promising 
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candidate that will fulfill at least some of the criteria for future development. It is thus impor-
tant to have a decent number of automated stations without losing the capacity to under-
stand and control the various parameters of such an assay.
We decided to go with small, independent stations that were not entirely automatized. One 
of the reasons for this choice was the fact that we could collaborate with the SIMM group that 
had all the capacities for running mammoth screen campaigns (over one million compounds). 
In addition, we believed—and still do—that some modularity is essential for the involvement 
of the technical personnel in these very repetitive tasks. Such modularity is more adaptive to 
numerous situations than a single, heavily integrated robot that will take weeks if not months 
to reconfigure for another assay, especially when the assays cover a very large spectrum of 
techniques. Indeed, we faced campaigns based on assays for widely different proteins and 
targets, including enzymes, receptors, protein-protein interactions, and channels, requiring 
being able to adapt the material at hand to the various approaches for screening these differ-
ent target types.
Another aspect that is particularly important for us is repeatability of the screens. Indeed, we 
chose to run assays in independent duplicates at two different calendar dates and possibly 
with two different operators, leading to a higher level of robustness for the results, as long as 
both results were close to each other (see below).
2.6. Screening
Screening is the modern version of intelligently seeking the needle in the haystack. It con-
cerns a test in which literally hundreds of thousands of compounds are evaluated, most of 
the time without any a priori information on their chemical structure or class (e.g., peptides, 
fragments, drug-like compounds, aptamers, toxins, natural extracts, natural compounds, 
etc.). Therefore, for cost constraint reasons, it may become important to screen in a smarter 
way [82]. This search has become a science in itself, a science that relies on chemical diver-
sity. We view it as follows: the more diverse the compound library is, the more chemical 
space it covers, and the more successful we might be in finding one or several hits for a 
particular target.
In a given library of compounds, what are the chosen compounds that will lead to a new 
drug (i.e. active, specific, non-toxic, and patentable)? A perspective from some leading phar-
maceutical companies was published in 2011 [83]. They gave their common view of the HTS 
programs, what they delivered, and what they failed to deliver. This particularly unusual 
publication (co-signed by the major pharmaceutical companies) exemplifies the reality of HTS 
expectations (too high) and of the quality/amounts of the results (the new drugs, too low). 
Nevertheless, as with the main progress in life science technologies in recent decades, the rise 
of HTS has led to plenty of new discoveries and approaches. We should not forget that all of 
these techniques accelerated discoveries, and even if those are not yet transformed into new 
drugs for the patient, they still add to the understanding of physiopathological processes. 
Mayr and Bojanic described the basic organization of an HTS laboratory—among other 
types—a few years back [84].
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2.6.1. High-throughput screening
We embarked about 15 years ago on establishing a minimal HTS department in which a 
couple of screening robots together with an integrated analysis system permitted ‘rapid’ 
screening of several thousand compounds. The adaptability of the machine quickly became a 
problem: expanding our screening capacity—in terms of diversity of assays as well as number 
of compounds—would require several identical instruments running in parallel on which 
specialized personnel would apply their skills in an unvarying way. We chose something 
else for a time. We aimed at having small stations independent from one another to be able 
to treat or read between 40 and 50 384-well plates (~15,000 compounds). There are no general 
rules about how to arrange such a laboratory: it depends on the space, money, and person-
nel available. We felt that the whole process should be rigorously simple, with several key 
steps (go/no-go decisions) from the basic setup of the assay (and its validation with reference 
compounds) to the automation and test on a small scale of 10,000 compounds and finally both 
full-deck campaigns.
Figure 2 shows a series of typical examples of data obtained with this set of methods. In 
general, we screened about 10,000 compounds using the final conditions (set up previ-
ously) in two independent campaigns with the same compounds and different operators, 
if possible. The analysis of those data is what will permit moving forward to the full 
campaigns of 250,000 compounds, tested twice on the target. Without going too much 
into practical details, we found this methodology to be the most appropriate. Even if 2 
or 3 out of 30 HTS campaigns turned out to be mute (no compound out of the HTS cam-
paigns), the rest delivered several classes of compounds that could be pushed to the pro-
gram downstream.
The figures show the repartition of the compounds according to their level of activity 
(left) while the graphs show the actual data where the results of the first test are plotted 
versus the second series of tests. The two tests are experimentally identical but run on a 
different day and if possible with a different operator. Because most of the compounds 
should be inactive, the Gaussian curves are centered to 0. The graphs should be aligned 
according to the diagonal of the rectangle because the data are theoretically identical, 
and should be massively located around 0. In Figure 2A, the first robotic setup led to a 
fat repartition of the compounds on the Gaussian curve, suggesting poor reproducibility, 
which is confirmed by the format of the correlation graph (or rather the lack thereof). In 
Figure 2B, with another setup, the data are more centered to the 0 and diagonal areas, 
respectively, in both figures, and in Figure 2C, the test was run first with a set of mol-
ecules, as in a feasibility attempt. We designated this process as a pre-HTS campaign. The 
data show a very good reproducibility of the tests, with compounds gathered along the 
diagonal of the graph.
2.6.2. HTS system: factory or small business?
It is the fashion to elaborate big systems that are very integrated and can run ‘any’ type of 
assays for any given number of compounds in a library. Unfortunately, despite beautiful 
examples of successful efforts with such machines, the issue of time frame in such situations 
is an elusive one. Indeed, moving on the same instrument from an enzymatic assay (e.g., with 
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fluorescent probes) to a cellular assay (e.g., with engineered cells) involves different instru-
ments, setups, and prerequisites. One cannot honestly predict the length the preparation will 
require, and to a certain extent, the length of the global process (assessment + campaigns).
Figure 2. A typical and real example of the influence of the robotic setup on the quality of the screening results. The test 
was a cellular-based assay (*), comprising the detection of an intra-organelle color change potentially due to the tested 
compounds (see Jensen et al. for full description of the test [85]). A and B show cellular-based assay results; * note the 
use of differentiated primary cells; C shows an enzymatic assay. All results (whatever the biological sources) should 
resemble panel C. Poor results such as A and B, even if partially corrected by adapting robotics (between A and B), 
would lead to massive amounts of false positive hits.
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In the particular case of cellular assays, and as discussed elsewhere, the use of cancer cell lines 
brings difficulties, due to their genetic baggage, that is, to say the least, abnormal, leading to 
overexpression of many proteins. Alternatively, cells might be primary cells differentiated or 
not, the use of which leads to major variations from cells to cells, ultimately leading to mas-
sive false positive amounts (up to 14%, see Figure 2) and poor reproducibility from batches to 
batches. Finally one possible choice would be to work with differentiated stem cells, as their 
robustness is enhanced due to the current state of the art, with more and more publications 
describing works in this area. All these cells can be engineered with modern transfection 
techniques.
It is always possible for extreme cases to use different approaches. For instance, in a pre-
modern time, we ran a HPLC assay for AANAT, ending with interesting hits despite the 
“low” number of compounds tested [67]. It is certainly an option whenever the available test 
involves extremely costly reagents or engineered fragile cells.
2.6.3. High-content screening (HCS) and its obligatory companion, functional genomic 
screening
High-content screening is a fast cellular-based approach that became possible in recent years, 
thanks to progress in imaging, computing, capturing, analyzing, and automating those pro-
cesses. Moffatt et al. has summarized these approaches [86]. One also has to keep in mind 
that whatever the complexity of the engineered cell-based assay that is designed to identify 
compounds specific to given (cellular) pathways, it is probably less complex than the cellular 
metabolism. In other words, once the compound has been identified, one must check the in 
situ nature of its target. Treatment of siRNA libraries of the cellular systems and/or reverse 
pharmacology can be used to such an end. Saeidnia et al. [87] has reviewed the reverse phar-
macology and possible solutions that are available.
The latest trend is to screen phenotypically engineered cells for the pathway in which the target 
is involved. If a compound is found, the validation process seems cumbersome to us. In fact, 
the deconvolution of the phenotype, to identify the actual target(s) of the hit compound(s), is 
a long process that is interesting, difficult, and expensive (in time and money). Cautions also 
have been published recently, warning scientists using such methodologies to be extremely 
careful in turning to these approaches because the number of biases is immense. We only very 
recently entered onto this path. In the meantime, we had serendipitously prepared the next 
steps by a very early attempt to industrialize our previous success in reverse pharmacology: 
the discovery of the third melatonin-binding site as quinone reductase 2 [43]. Nevertheless, 
this success has not been the rule. Several attempts done internally to find the target of given 
pharmacological agents have so far failed.
2.7. Screening what?
At the start of the year 2000, the question was, “How many compounds do you have in your 
library?” Without reference to the diversity of the compounds, some big players in the game 
had more than a million compounds available. Indeed, diversity is a complex problem that 
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has been discussed at length by various authors (see Gillet et al., in particular [88, 89]). In the 
chemist community, it is often joked that there are as many definitions of diversity as individ-
ual chemists. Briefly, we chose to stay on the following path. Based on a definition of diversity 
that we found clear and attractive [90] and that gather all the basic concepts of diversity (and 
their measurement), we chose to base our own measure of diversity on the pharmacophore 
concept [91]. We felt that the more we wanted to pinpoint this diversity concept, the more we 
became lost in endless descriptors of the molecules [92]. Ultimately, we used the approach 
of Lepp [93] to establish a representative sub-library of compounds that can serve as a sim-
plification of our complete library for pre-test purposes (see above) or to limit the number of 
compounds whenever the screening campaign uses a test that is either too expensive or cellu-
lar (i.e., “too” complex). Another way to define diversity is to measure the similarity between 
compounds, another approach that has also been discussed at length [94].
The diversity of the product collection that will be tested is indeed important and allows for 
anticipation of the discovery of new series on which the medicinal programs will be devel-
oped. Achieving diversity, however, will require the inclusion in the library of compounds 
with unusual or poorly documented structures.
A company like ours has a 60-year history of chemical synthesis of drug candidates. These 
molecules are still available in the compound collection and constitute an original source of 
diversity. To complete this panel while maintaining the largest diversity possible, we chose 
to integrate into the compound library natural pure products, extracts, peptides, and more 
generally ‘drug-like’ chemicals either synthesized internally or commercially available. We 
targeted having a total of about 250,000 compounds screened, systematically, for any targets 
of interest.
2.7.1. Natural compounds
A fundamental in this domain is certainly the belief that ethnopharmacology can identify 
interesting natural molecule(s) from traditional medicine (see Heinrich et al. for background 
in ethnopharmacology [95]). Ethnopharmacology focuses on a compendium of mixtures that 
medical practitioners in native populations prepared and gave to their patients, sometimes 
with outstanding success. The complexity of these approaches is immense. Indeed, besides 
the type of the plants used—not always easy to trace and not always easy to find in historical 
locations—there is the nature of the preparation, including the mixture of several different 
plants and associated products (of animal [including insects] or mineral origin). We tried to 
access the two main available sources of such compounds: pure compounds or extracts that 
need to be deconvoluted, usually by bio-directed strategies. We have reported our experi-
ences with the latter in three publications [96–98] but rapidly abandoned these approaches 
for the following reasons: paucity of results; tediousness of the process; difficulty in repeating 
the exact same experiment, including trouble finding plants at the same location with the 
same properties; and last but not least, often difficulties with the structure identified, which 
turned out to be common or of a complexity beyond the reasonable feasibility of industrial 
production. It remains interesting to view those compounds as a mold of the target binding 
site and/or to use them as an inspiration for a future drug. At the other end of the spectrum, 
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commercially available, pure compounds are hard to find in a decent quantitative supply. 
Often, compounds are available from vendors, but they are either common (flavonoids, cou-
marins, peptides, terpenoids, and alkaloids) or provided in minute quantities, with barely 
any reload possible. We therefore balanced our library with some of those pure compounds, 
as an internal control to assay, because often flavonoids—while poorly soluble—have turned 
out to be enzyme inhibitors (see, for example, [40, 99]).
In the interest of completeness, we add that one other path is to provide some biotech compa-
nies with a target. They screen the target with their proprietary sources of natural compounds 
(often as microorganisms, plants, and similar extracts to start with).
2.7.2. Peptide libraries
We became interested in peptide combinatorial libraries at the very beginning of this approach 
and studied several aspects of those libraries: numbers [100], quality control [101], and activ-
ity [102, 103]. For solid-phase synthesis approaches, the actual number of peptides in a given 
library is limited by the availability of amino acids on the resin, and that number is limited by 
the number of individual peptide repeats in the initial mixture, which is obviously by far the 
most complex one. The trick turned out to be the way syntheses were conducted, by having 
the last amino acids as a constant in each vessel (see Houghten et al. [104]). Regardless, these 
approaches are often interesting to follow, particularly when soluble or secreted targets are 
concerned.
2.7.3. Compound libraries
Despite the large diversity of compounds available for screening, whether through scientific 
collaboration, subcontracts, or vendors, the nature of the compounds is one of the most sensi-
tive secrets of the pharmaceutical companies. As stated above, we attempted to complement 
our more than 60 years of internal chemical synthesis with compounds bought or synthesized 
with the greatest care to try to achieve the widest diversity of compounds and to be able, at the 
end of the screening process, to validate original molecules with great potential. This strategy 
is based on our capacity to analyze and understand chemical diversity and thus be able to 
predict what should be synthesized to fill in the gaps in this diversity picture.
2.8. Choosing the hits for further programs
The question here is, “Choosing among which hits and why?” In the industry, the answer is 
simple: to heal and to make a drug. For other scientists, the answer might be slightly differ-
ent: understanding a pathway (such as those at the core of a pathology) or finding tools that 
permit the study of the pathology, the receptor, or the enzyme. In any case, the path from hits 
to lead and then from lead to candidate is particularly long and painful. Thus, the structure 
of the various candidates (often from two or three different families of compounds) must be 
chosen extremely carefully to avoid the various obstacles: chemistry difficulties, including 
that the drug will be synthesized at the ton level at the end; specificity towards the other pro-
teins of the body (not less); pharmacokinetics (often the compound should be given orally); 
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and patentability. It is interesting to note that exceptional universities, such as the University 
of Michigan, have published their reflections on this subject [105]. On the other hand, one 
should realize that the hit rate of an ab initio screening is somewhere between 0.01 and 0.1%. 
For 250,000 molecules, that translates to 25 and 250 compounds. It looks like plenty to choose 
from, although the hope is that among those compounds, some are similar, suggesting a 
structure-activity relationship that enforces the results of the HTS.
Sometimes, as noted, researchers will choose compounds for their availability or their known 
lack of toxicity, despite other problems such as a lack of specificity. The purpose then is dif-
ferent: finding tools to validate a pathway or the engagement of a target in a given pathol-
ogy (see Section 2.2). Examples like melatonin [106], curcumin [107], or resveratrol [108] are 
also interesting to note. Indeed, these compounds are fantastic tools to better understand a 
network of pathways involved in various pathologies, but none of them shows any type of 
specificity. To the contrary, they seem active in many pathological situations because they 
interfere with many targets.
A more recent approach has also involved the systematic use of chemoinformatics analyses 
with its formidable capacity of calculus and prediction [109, 110]. Starting from there, it is 
possible to rationalize the choice of the best hits: among others, the previous history of the 
compound in the earlier campaigns on other targets, similarity with known compounds from 
the literature, patentability, and accessibility to the chemistry (not too complicated to allow 
‘easy’ generation of a large series of analogues).
2.9. Confirming the hit activity
Once hits have been identified, the process continues in validating the molecules in their 
recorded interaction with the targets. Genick and Wright [111] addressed this subject, among 
others, in their recent paper. Essentially, it comprises three aspects: biochemical validation, 
biophysical measurement, and structural data.
Our first step is towards an orthogonal confirmation of the activity of the compound. 
Obviously, whenever an enzyme is concerned, it is ‘quite easy’ to invent or copy an alternative 
assay that engages different physical parameters, going from the old, global, radioactive phos-
phocellulose paper-based detection assay [112] to a more specific radioactivity-based assay 
[113] for a kinase, for instance; trying to go from a protein-based phosphorylation assay [114] 
to a more specific peptide-based assay [66] or lastly, going from an antibody-based assay to 
a more specific ubiquitinated peptide-based assay [115]. There are multiple examples of such 
orthogonal assays, such as the use of HPLC, fluorescence polarization, mass spectrometry, 
and fluorescence resonance energy transfer (FRET) technology. We always felt that part of the 
reproducibility problem(s) was (were) due to the result of the poorly understood interferences 
between components of the assay, even sometimes the totally aspecific actions of the com-
pound onto the target, for instance, by precipitating the protein rather than inhibiting it, with 
a similar effect in the assay (lack of activity in the presence of the compound). Compounds at 
the concentration used in the screening process—often 10 μM—tend to precipitate. The addi-
tion of dimethylsulfoxide (DMSO) as a compatible organic solvent limits this precipitation to 
a certain extent, but the presence of DMSO might affect the enzyme or the reactivity medium 
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(not to mention the receptor, membrane-bound assay). This is also why we argue for work on 
purified targets to simplify, at least in this context, the environment of the protein.
For the receptor assay, it can be more complicated to find an alternative, often because of the 
uniqueness of the radioactive ligand used in the binding assay. We tried to circumvent this 
problem by developing options in this context, for example, in synthesizing other ligands, to 
have more than a single binder in our melatoninergic [116, 117] or MCH toolboxes [118]. If 
this goal is achievable for receptors that have been studied for decades (serotonin, adenosine, 
histamine, and melatonin), for other more recently studied receptors, it has been completely 
impossible, including the obvious case of orphan receptors for which ligands are not known 
and assays are built around receptor functionality. Thus, the study of such receptors has 
largely been done through efforts to de-orphanize them [119, 120] and to fully characterize 
them with all the tools of molecular pharmacology, as for gpr103 [121–124] or gpr50 [125, 126]. 
An easier alternative is to work with known ligands as peptides, as in our extensive work on 
melanin-concentrating hormone for which alterations in the natural sequence led to alterna-
tive ligands [118], agonists [127], or antagonists [28, 128]. Beyond the thrill of executing a tour 
de force design and the joy of manipulating peptides of short sequences, with their infinite 
possible variations, the work brought a panel of new tools that might ultimately contribute to 
understanding such integrated systems.
2.10. Structuring: what is the hit/target relationship at the atom level?
As noted, part of the validation is linked to the visualization of the molecular structure of 
the complex between the hit and the target. The key role of this approach has been reviewed 
numerous times (e.g., Scapin [129], Hu et al. [130], and Zheng et al. [131, 132]). It is now clear 
that the progression of the compounds from a hit to an elaborate drug will benefit immensely 
from structural biology data. We contributed also to a certain vision of how alternative meth-
ods will complete (and possibly compete with?) crystallography, particularly cryo-electronic 
microscopy [133].
We made the choice of an active and ambitious structural biology approach about 10 years 
ago. Creating efficient collaborations with some groups, our first attempts were to character-
ize the interactions between some of our compounds and a given target in neurogenerative 
diseases [134–136]. We then embarked on several kinase-related projects that ended with the 
discovery of powerful compounds [137–140]. However, we needed more freedom to oper-
ate and establish proof of concept of the importance of these approaches to complement our 
drug discovery programs. For this reason, we chose to install a dedicated laboratory inside 
a synchrotron (Soleil, St. Aubin, France) to gain full access not only to the beamlines but also 
to the vast scientific community behind this instrument. This choice led to several collabora-
tive academic-oriented lines of research [136, 141] and to more internal research programs. In 
preparing the next steps of crystallization—the step involving the receptor and more gener-
ally membrane proteins—we assessed a series of methodologies for the solubilization and 
purification of functionally competent receptors [56, 57]. Furthermore, we also studied the 
impact of microfluidics on crystallization of proteins for structural biology studies [142, 143].
The companion science of structural biology is molecular modeling. It is key for discovery pro-
grams, either at the early stage (explaining and rationalizing the molecule-target relationship 
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and even quantifying it) or at a later stage when new molecules, derived from a hit in the 
screening campaign, will be synthesized and need to be paused inside the structure of the tar-
get by calculation or co-crystallization. We have reported some examples of the use of those 
techniques for glucokinase [144], gpr103 [124], and rev-erbα [145].
2.11. “Biophysing”: understanding and measuring the forces responsible for the 
relation between the molecule and its target
Many reviews have nicely summarized recent community perspectives on this aspect of 
compound characterization [146–148]. No doubt, the rise of all the physical biology methods 
affords more and more tools that are essential to a modern drug discovery program, particu-
larly when trying to understand and measure the relationship between the compound—that 
is, the drug candidate or its ancestor—and its protein target.
From the seminal work—for us—of Shuman et al. on HIV proteases [149], we started to won-
der if the complicated concepts of thermodynamics could be applied to the process of moving 
from hit to lead compounds. What would be the help of measuring the actual parameters 
of a target-compound association, even if the target were not a receptor but an enzyme? We 
became adopters of surface plasmon resonance (SPR) [150], calorimetric instruments, fast-
flow machines to measure events of enzymatic activity that occur faster than a second [151], 
and native mass spectrometry to gain information on the minute conformational changes of 
proteins [152].
It is now clear that those tools have become part of ongoing studies for helping medicinal 
chemists better evaluate and thus better understand the impact of the minute modifica-
tions they make to their compounds. For instance, the use of calorimetry to determine 
the actual affinity of an inhibitor for its enzyme has proved to be accurate [134], while 
standard methodologies such as binding turned out to be cumbersome if not wrong [153]. 
Furthermore, the determination of the number of compounds and their nature associated 
with a given protein was also a key step in our understanding of quinone reductase 2 
enzymatic behavior [70].
These “new” tools are increasingly reliable. “Structuring” and “biophysing” help give access 
to precise details on the structure of the co-crystal together with actual thermodynamics mea-
sures and thus the relationships at the atom level between the target and its ligand (at least, 
and for the moment, for enzymes); however, crystallization of the membrane-bound proteins 
(such as GPCRs) is still a challenge, despite recent major progress [154, 155]. These newer 
tools permit visualization and quantification of these interactions. The medicinal chemist can 
use this information as the basis for a synthesis strategy for the evolution of hits towards a 
series of compounds with ad hoc properties that are easier to predict and rationalize.
3. What next?
Research has always been a question of strategic and/or opportunistic decisions at a given 
time to explore areas that look promising for a better future. These decisions, at the industry 
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level, are always difficult to make. Money, time, and energy go into anticipating what will be 
important—technology-wise—for the next decade of discovery.
Among the published reports that we attempted to explore were many approaches involv-
ing new, non-invasive techniques to better understand the role of a compound and its target 
inside a cell, the future of stem cells and of chemical proteins, and the modifications of pro-
teins inside the cells.
3.1. Stem cells as expressing systems
Stem cells have been the new frontier for some time and remain so. One debate has been 
whether to target therapy with stem cells, directly (in cell therapy) or indirectly (by using the 
secretosome of differentiated stem cells) or to use the cells as hosts for a target that would 
then be expressed in an optimal environment, as opposed to the classical use as hosts of 
cancer cell lines that are either very derived from the original cell lines or comprise numer-
ous nuclei with profoundly abnormal karyotypes. We chose the isolation, differentiation, 
production, and characterization of such stem cell-derived cardiomyocytes [156]. Potentially, 
these techniques open new roads to the use of natural hosts that would be a better context for 
the expression of targets in a natural environment. Furthermore, as demonstrated in several 
instances, stem cells can be derived from patients, and some can recapitulate the disease at 
the cellular level, leading to a possibly better understanding of the molecular cause(s) of a 
given disease [157, 158].
It might be important in the coming years or decades to be able to cope with the therapeutic 
use of such stem cells, despite initial concerns [159] and the extraordinary characteristics [160] 
of these cell types.
3.2. Chemical proteins
A boom in the area of chemical proteins followed the discovery—among others—of chemi-
cal ligation [161]. It became possible to synthesize enzymes chemically and measure their 
catalytic activity. After the chemical synthesis (by solid-phase synthesis) and use of ubiquitin, 
described for several decades, we chose a small enzyme (120 aa), calstabin, that we completely 
synthesized with our partner. We crystallized this enzyme and measured its catalytic activity. 
In doing so, we learned two important things: (1) such an approach is feasible, even though it 
led to small quantities of material, at least to start with, and the material was indistinguishable 
from the recombinant version and (2) the apparent mono-peak analysis of the result of the 
synthesis revealed, after further analyses, that the protein could be separated in two distinct 
peaks, one a fully refolded protein with catalytic activity and the other a denatured protein 
with no catalytic activity and no refolding [141]. These findings led us to consider that large 
peptides/proteins that are chemically synthesized and often described as being used in the 
literature (e.g., EPO, growth factors) might be a mixture of active and inactive substances if 
not appropriately characterized.
Our aim was and still is the validation of a process encompassing both the recombinant 
expression of pieces of a large protein—such as an antibody—that contained only natural 
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amino acids and other pieces of the same protein, in which exotic amino acids were inserted. 
The fusion between those pieces would then be performed by chemical ligation(s). These 
approaches will open avenues to the incorporation of key functional groups in protein for 
derivatization with drugs (antibody-drug conjugates) or to incorporation into proteins of 
exotic chemical functions.
3.3. Ligases
Among the seminal studies of the in cellulo modifications of proteins are the numerous 
efforts of Alice Ting’s group [162]. Using a modified ligase, it became possible to directly 
label target proteins in a cellular context. The label can be a fluorophore, radiolabeled com-
pound, or NMR probe, for example, and the chemistry of the modification is the main 
limitation of this process. Coupling it with the power and resolution of magnifying instru-
ments, including specialized beam lines in a synchrotron, can lead to the cartography of 
the protein inside a living cell. We began the process first by characterizing the enzymology 
beyond this ligase-catalyzed enzymatic reaction, using purified enzyme and reagents in an 
acellular context [163]. This technique will be adapted to intracellular processes with the 
goal of modifying a recombinant protein in situ and to allow labeling of a protein inside the 
cell to follow its fate.
4. Outside the box
Anticipating tomorrow’s needs in modern research is a challenge that requires triangulating 
the many different areas necessary for drug discovery. It has thus been difficult to choose vari-
ous avenues to make our efforts more successful, modern, and interesting and at the service of 
future trends and needs in drug discovery for therapies and cures. Choosing to enhance our 
capacities to incorporate new approaches is always a challenging but moderate risk, based on 
the way we perform these exploratory strategies. Indeed, one critical choice was to hire post-
docs to scrutinize those ideas. In doing so, we not only identified and incorporated strong 
scientists but also could assign new technologies to categories such as ‘dream’, ‘usable soon’, 
‘needs more time’, etc. Among the discoveries that we have published are the ligase use for 
in cellulo transformation of proteins [163], including antibodies; cellular imaging using large 
synchrotron instruments; synthetic proteins that can be as active as the recombinants [141]; 
and synthesis of proteins and peptides modified by ubiquitination the way it happens in the 
cell (as opposed to what was commercially available at that time) [115]. In addition, we started 
our first trials in thermodynamics, structural biology, new crystallization techniques, native 
mass spectrometry for structural biology approaches [152] and for target-molecule relation-
ships, and the use of human stem cells as an alternative to rat cardiomyocytes in first culture, 
among other initiatives.
The engineering of cells and their use as therapeutic agents bring new challenges and new 
wonders almost daily. New challenges emerge because the necessary work to achieve thera-
pies for tomorrow may not necessarily be what was done in the recent past. These challenges 
On the Organization of a Drug Discovery Platform
http://dx.doi.org/10.5772/intechopen.73170
35
often require new approaches, particularly in the use of treatments with stem cells from the 
patient, or with cells that have been engineered to fulfill a task that only science fiction writ-
ers dreamed about in the 1950s. Just one example is the seminal paper by Schukur et al. [164] 
on the possibility of engineering a cell to produce a factor (such as tumor necrosis factor) 
following a native regulatory pathway in the patient in whom these cells will be grafted. The 
number of new technologies required to reach that end is just immense. If we do not prepare 
for such wonders, the industry will have an extremely complicated time reorienting to tomor-
row’s health-related demands.
5. Conclusions
The body of techniques developed and applied in the DD platform throughout the years 
has contributed to the introduction of several molecules on the market. The contribution 
of this platform concerned the initial steps of compound discovery that proceeded towards 
final molecules. Or else, the platform was involved in providing data on the biophysics of 
the interaction, most of the time, all steps of drug discovery contributed to the final results. 
Some findings have been published and showed the completeness of the approach that 
laid the foundations for the discovery and early clinical development of drug candidates 
[138, 139, 165].
There is obviously confusion between the use of research that is the replication of data 
obtained elsewhere (the role of the industry) and the de novo research programs that are 
developed in the pharmaceutical industry. The confusion is that work consisting of new 
research should not be done in the industry, but in academic institutions, while repeating 
published data should be done in the industry. In that way, by limiting the novelty of the 
industrial work, the novelty of the cure(s) found in such context might be limited, thus 
leading to a situation where alternate paradigms must be found. For instance, a way to 
access to novelty might be to fund biotechnology companies to explore new research areas 
and new ideas.
To echo arguments already made above, most of the published research is difficult (if not 
impossible) to repeat. And as noted, there has been a long debate in the scientific literature on 
the repeatability of data [166, 167]. Therefore, part of any efforts at clarity and repeatability 
should be sorting the reality from the fantasy in what we are reading. Furthermore, the key 
to success is often to be the one company that delivers first on something for the patients’ 
benefit. Anyone coming in after the first- or second-place entry will be less rewarded. As 
mentioned in the introduction, research attrition in the pharmaceutical industry is around 
90%, meaning that 9 out of 10 projects fizzle before reaching the clinic. In the meantime, the 
(discovery) show must go on, and the company must sustain this endeavor with internal and 
investor money or turn to other sources of innovation.
Finally, research is a never-ending dynamic process. If development of new techniques and 
new concepts ceases, such a drug discovery platform can rapidly become obsolete.
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